Nov. 17, 2020—Qiagen announced the European launch of the NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage test, which aims to help health care professionals identify and differentiate between patients with common seasonal respiratory infections and COVID-19. The multiplex PCR test detects and differentiates influenzas A and B, respiratory syncytial virus, and SARS-CoV-2 infections within 80 minutes.
NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage is CE-IVD marked and has been submitted to the FDA for emergency use authorization.